Publications by authors named "Teruki Isobe"

Article Synopsis
  • The study looked at how well different medicines work against a bacteria called Staphylococcus saprophyticus that can cause a bladder infection (acute cystitis) in Japan.
  • Researchers checked medical records from ten hospitals to see what treatments worked best and how many patients got better.
  • Most of the medicines worked really well, and only one patient didn’t get better, showing that the bacteria didn’t resist the treatments very much.
View Article and Find Full Text PDF

Introduction: Avelumab (Ave) is approved for metastatic urothelial carcinoma (mUC) maintenance therapy and prolongs overall survival (OS). We explored trends related to Ave treatment of mUC patients.

Methods: A total of 72 patients with mUC treated with first-line chemotherapy, from January 2019 to November 2022, at our affiliated institutions, were analyzed.

View Article and Find Full Text PDF
Article Synopsis
  • The EV-301 trial demonstrated that enfortumab vedotin improved survival for patients with advanced urothelial carcinoma previously treated with specific therapies, but data in Asian populations were lacking.
  • A study of 61 Japanese patients showed that enfortumab vedotin was effective, with a median overall survival of 17.1 months and common side effects including skin issues and neuropathy.
  • The C-reactive protein level emerged as a potential prognostic marker for better survival outcomes in patients receiving enfortumab vedotin, although patient characteristics were similar across different CRP levels.
View Article and Find Full Text PDF

We elucidated the efficacy of gut microbiome-altering drugs on pembrolizumab efficacy in patients with metastatic urothelial carcinoma (mUC). Clinical data were analyzed retrospectively from 133 patients with mUC who received second-line pembrolizumab therapy between January 2018 and January 2021, following failed platinum-based chemotherapy. We evaluated the effects of gut microbiome-altering drugs (proton pump inhibitors [PPI]/potassium-competitive acid blockers [P-CAB], H2 blockers, antibiotics, non-steroidal anti-inflammatory drugs [NSAIDs], metformin, antipsychotics, steroids, and opioids), taken by patients within 30 days before/after pembrolizumab treatment, on progression-free survival (PFS) and overall survival (OS).

View Article and Find Full Text PDF

Introduction: This study evaluated the prognostic value of a sustained high Geriatric Nutritional Risk Index (GNRI) during first-line chemotherapy for patients with metastatic urothelial carcinoma (mUC).

Methods: Between January 2018 and February 2022, 123 patients received platinum-based chemotherapy at Nagoya City University Hospital and affiliated institutions. Of these, 118 eligible patients who showed an Eastern Cooperative Oncology Group performance status (ECOG-PS) between 0 and 2 were retrospectively examined.

View Article and Find Full Text PDF

Purpose: This study aimed to analyze a feasible and suitable surgical precautionary preparatory technique. The techniques of double-gloving with hygienic hand wash (DH) and single-gloving with surgical hand wash (SS) were compared for their ability to prevent postoperative infection in robotic and laparoscopic minimally invasive surgeries.

Materials And Methods: A prospective, non-randomized, multicenter study was conducted between January 2016 and June 2020.

View Article and Find Full Text PDF

Introduction: Hemorrhagic cystitis is characterized by gross hematuria, with hemorrhagic shock a rare complication. However, to our knowledge, its exact frequency has not been reported.

Case Presentation: We report a case of an 86-year-old woman who showed repeated hemorrhagic cystitis with massive bleeding and hemorrhagic shock.

View Article and Find Full Text PDF
Article Synopsis
  • After first-line chemotherapy failure, metastatic urothelial carcinoma (mUC) patients were treated with either pembrolizumab (PEM) or a combination of gemcitabine and docetaxel (GD), with this study analyzing their second-line treatment outcomes.
  • Among the 198 patients studied, those treated after the introduction of immune checkpoint inhibitors (Group B) had a significantly longer median overall survival (OS) of 13.6 months compared to 7.6 months in the previous treatment era (Group A).
  • The research found that low neutrophil-to-lymphocyte ratio (NLR) and high geriatric nutritional risk index (GNRI) were key factors impacting longer survival times in these patients
View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to evaluate the modified Glasgow prognostic score (mGPS) as a predictor for the prognosis of patients with metastatic urothelial carcinoma (mUC) undergoing different treatments.
  • - It involved 142 patients, with 68 receiving gemcitabine/cisplatin and 74 receiving pembrolizumab, showing that a higher mGPS correlated with poorer progression-free survival (PFS) and cancer-specific survival (CSS) in both treatment groups.
  • - The findings indicated that patients with a high mGPS had shorter survival rates, establishing it as a significant risk factor for poor CSS in mUC patients undergoing these therapies.
View Article and Find Full Text PDF

Objectives: The aim of the study was to examine the effectiveness of a modified-short hydration gemcitabine and cisplatin (m-shGC) regimen for patients with metastatic urothelial carcinoma (mUC) and to assess the efficacy of a geriatric nutritional risk index (GNRI) with regard to prognosis.

Patients And Methods: From January 2016 to July 2020, 68 patients with mUC underwent first-line m-shGC therapy with 70 mg/m2 cisplatin and 1,000 mg/m2 gemcitabine (days 1, 8, and 15), with 2,050 mL fluid replaced on the first day of each 28-day cycle. Prior to the start of treatment, the serum neutrophil-to-lymphocyte ratio (NLR), and levels of albumin and C-reactive protein (CRP) in serum, as well as body heights and weights were measured.

View Article and Find Full Text PDF

Introduction: Immunoglobulin G4-related disease embraces a wide range of extra-pancreatic manifestations. However, localized pathogenesis in gonadal glands, including testes or seminal vesicles, is rare. The clinical course and therapeutic strategy for this disease have not been clearly characterized.

View Article and Find Full Text PDF

The number of patients with urothelial carcinoma (UC) is high, with a corresponding demand for detecting UC easily and non-invasively. Cystoscopy and urine cytology, with widely known diagnostic accuracies, are the gold standards for identifying UC originating from the bladder. However, cystoscopy or other tests, such as ureteroscopy or retrograde pyelography, are uncomfortable for patients.

View Article and Find Full Text PDF